Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Premasol is a sterile, nonpyrogenic solution of essential and nonessential amino acids specifically designed for neonates and infants requiring parenteral nutrition. It serves as a nitrogen source to promote protein synthesis and wound healing, and to reduce the rate of protein catabolism in patients where the oral or enteral route is inadequate or impossible. The formulation is tailored to meet the unique metabolic needs of premature and low-birth-weight infants, often containing higher concentrations of certain amino acids like tyrosine and histidine compared to adult formulations. It is typically administered via central or peripheral intravenous infusion as part of a total parenteral nutrition (TPN) regimen. The Women and Infants Hospital of Rhode Island has utilized Premasol in clinical trials to evaluate whether early aggressive protein intake improves growth and neurodevelopmental outcomes in very low birthweight infants.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Premasol.